MedTrace Logo

The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

NCT03509688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2018-04-26

No results posted yet for this study

Summary

The purpose of this study is to use entecavir combined with other drug such as resveratrol and thymosin to treat patients with hepatitis B, which may provide a novel therapy target hepatitis B.

Conditions

  • Hepatitis

Interventions

DRUG

entecavir+resveratrol

entecavir+resveratrol

DRUG

Entecavir

Entecavir

DRUG

entecavir+thymosin α1

entecavir+thymosin α1

Sponsors & Collaborators

  • Chinese Academy of Sciences

    collaborator OTHER_GOV

  • The First Hospital of Jilin University

    lead OTHER

Principal Investigators

  • Junqi Niu, PHD · The First Hospital of Jilin University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509688 on ClinicalTrials.gov